Regulation of the cyclin-dependent Kinase Inhibitor p57Kip2 expression by p63

Cell Cycle

Volumn 4, Issue 11, 2005, Pages 1625-1631

  Beretta, Chiara ^a   Chiarelli, Anna ^a   Testoni, Barbara ^a   Mantovani, Roberto ^a   Guerrini, Luisa ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Department of Biomolecular and Biotechnological Sciences ^*  (Italy)

Author keywords

p63 p57Kip2 development

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P57; PROTEIN P63;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPORTER GENE; TRANSACTIVATION;

EID: 27744597937     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.11.2135     Document Type: Article

References (36)

1. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-4.
2. Sherr CJ. Cancer cell cycles. Science 1996; 274:1072-7.
3. Nakayama K, Nakayama K. Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays 1998; 20:1020-9.
4. 1-phase progression. Genes Dev 1999; 13:1501-12.
5. Nagahama H, Hatakeyama S, Nakayama K, Nagata M, Tomita K, Nakayama K. Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27Kip1 and p57Kip2 during mouse development. Anat Embryol (Berl) 2001; 203:77-87.
6. Westbury J, Watkins M, Ferguson-Smith AC, Smith J. Dynamic temporal and spatial regulation of the cdk inibitor p57Kip2 during embryo morphogenesis. Mech Dev 2001; 109:83-9.
7. Hatada I, Mukai T. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 1995; 11:204-6.
8. Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg AP. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 1996; 93:3026-30.
9. Taniguchi T, Okamoto K, Reeve AE. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour. Oncogene 1997; 14:1201-6.
10. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57kip2, a structurally distinct member of the p21CIP1 CDK inhibitor family, is a candidate tumor suppressor gene. Genes Develop 1995; 9:650-62.
11. Hoovers JM, Kalikin LM, Johnson LA, Alders M, Redeker B, Law DJ, et al. Multiple genetic loci within 11p15 defined by Beckwith-9- Wiedemann syndrome rearrangement breakpoints and sub chromosomal transferable fragments. Proc Natl Acad Sci USA 1995; 92:12456-60.
12. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997; 387:151-8.
13. Yan Y, Frisen J, Lee MH, Massague J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997; 11:973-83.
14. Takahashi K, Nakayama K, Nakayama K. Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem 2000; 127:73-83.
15. Balint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA 2002; 99:3529-34.
16. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
17. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13.
18. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8.
19. Van Bokhoven H, Brunner HG. Splitting p63. Am J Hum Gen 2002; 71:1-13.
20. van Bokhoven H, McKeon F. Mutations in the p53 homolog p63: Allele-specific developmental syndromes in humans. Trends Mol Med 2002; 8:133-9.
21. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, Delattre O. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001; 20:3258-65.
22. Shin JY, Kim HS, Park J, Park JB, Lee JY. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cell. Cancer Res 2000; 60:262-5.
23. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, Metcalf RA, Stampfer MR, Fusenig N, Rogan EM, et al. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 1993; 5:833-9.
24. Figliola R, Maione R. MyoD induces the expression of p57Kip2 in cells lacking p21Cip1/Waf1: Overlapping and distinct functions of the two cdk inhibitors. J Cell Physiol 2004; 200:468-75.
25. Gartel AL, Tyner AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999; 246:280-9.
26. Liu G, Xia T, Chen X. The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem 2003; 278:17557-56.
27. Williamson EA, Dadmanesh F, Koeffler HP. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 2002; 21:3199-206.
28. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004; 61:822-42.
29. Ghioni P, Bolognese F, van Bokhoven H, Mantovani R, Guerrini L. Transcriptional effects of p63 isoforms; identification of novel activation and repression domains. Mol Cell Biol 2002; 22:8659-8668.
30. Ghioni P, D'Alessandra Y, Mansueto G, Jaffray E, Hay RT, La Mantia G, Guerrini L. The protein stability and transcriptional activity of p63α are regulated by SUMO-1 conjugation. Cell Cycle 2005; 4:183-190.
31. 2/M promoters. Mol Cell Biol 2005; 9:3737-51.
32. Dohn M, Zhang S, Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20:3193-205.
33. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277:18817-26.
34. Di Iorio E, Barbara V, Ruzza A, Ponzin D, Pellegrini G, De Luca M. Isoforms of {Delta}Np63 and the migration of ocular limbal cells in human corneal regeneration. Proc Natl Acad Sci USA 2005; 102:9523-8.
35. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001; 98:3156-61.
36. Vanderhooft SL, Stephan MJ, Sybert VP. Severe skin erosions and scalp infections in AEC syndrome. Pediatr Dermatol 1993; 4:334-40.